Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 10/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 10/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21105707 | 1.00 | ATM (0.47) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL5644039 | 0.85 | ATM (0.50) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3855815 | 0.85 | ATM (0.66) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3397495 | 0.85 | ATM (0.50) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3763134 | 0.85 | ATM (0.50) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL19119305 | 0.85 | ATM (0.66) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL1155138 | 0.85 | ATM (0.50) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL23201647 | 0.83 | ATM (0.69) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL13237028 | 0.83 | ATM (0.69) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL27627180 | 0.83 | ANPEP (0.46) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591212-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-114591212-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ATM 2327/4885PIK3CD 2215/4885DPP4 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.